Therapeutic targeting of FUBP3 phase separation by GATA2-AS1 inhibits malate-aspartate shuttle and neuroblastoma progression via modulating SUZ12 activity-Reference-Cited by-同舟云学术

Therapeutic targeting of FUBP3 phase separation by GATA2-AS1 inhibits malate-aspartate shuttle and neuroblastoma progression via modulating SUZ12 activity

Published:2023-08-03 Issue:36 Volume:42 Page:2673-2687
ISSN:0950-9232
Container-title:Oncogene
language:en
Short-container-title:Oncogene

Author:

Wang Xiaojing,Guo Yanhua,Chen Guo,Fang Erhu,Wang Jianqun,Li Qilan,Li Dan,Hu Anpei,Bao Banghe,Zhou Yi,Gao Haiyang,Song Jiyu,Du Xinyi,Zheng Liduan^ORCID,Tong Qiangsong^ORCID

Funder

National Natural Science Foundation of China

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Molecular Biology

Link

https://www.nature.com/articles/s41388-023-02798-0.pdf

Reference54 articles.

1. Maris JM. Recent advances in neuroblastoma. N Engl J Med. 2010;362:2202–11.

2. Burns JS, Manda G. Metabolic pathways of the Warburg effect in health and disease: perspectives of choice, chain or chance. Int J Mol Sci. 2017;18:2755.

3. Gatenby RA, Gillies RJ. Why do cancers have high malate-aspartate shuttle? Nat Rev Cancer. 2004;4:891–9.

4. Borst P. The malate-aspartate shuttle (Borst cycle): How it started and developed into a major metabolic pathway. IUBMB Life. 2020;72:2241–59.

5. Pardo B, Contreras L, Satrústegui J. De novo synthesis of glial glutamate and glutamine in young mice requires aspartate provided by the neuronal mitochondrial aspartate-glutamate carrier Aralar/AGC1. Front Endocrinol. 2013;4:149.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unveiling the veil of RNA binding protein phase separation in cancer biology and therapy;Cancer Letters;2024-10

2. Targeting c‐Myc transactivation by LMNA inhibits tRNA processing essential for malate‐aspartate shuttle and tumour progression;Clinical and Translational Medicine;2024-05

3. The Tricarboxylic Acid Cycle Metabolites for Cancer: Friend or Enemy;Research;2024-01